Skip to content

Digital CBT-I for Insomnia Disorder

Clinical Effectiveness of Digital CBT-I for the Treatment of Insomnia Disorder: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05541055
Acronym
CrEDIT
Enrollment
336
Registered
2022-09-15
Start date
2022-11-08
Completion date
2023-08-24
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia Disorder

Keywords

Insomnia, digital CBT, CBT-I

Brief summary

This study will examine the effectiveness of digital CBT-I versus sleep hygiene education in reducing insomnia severity, sleep onset latency, and wake after sleep onset in those with insomnia disorder.

Detailed description

This study aims to examine the effectiveness of a fully-automated web and app-based digital CBT-I for insomnia compared to sleep hygiene education (SHE) in individuals with a diagnosis of insomnia disorder. Primary outcomes of interest include changes in insomnia severity, sleep onset latency, and wake after sleep onset throughout the course of the study.

Interventions

A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.

OTHERSleep hygiene education

Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm. Participants will be able to revisit content during the trial as they wish.

Sponsors

University of California, San Francisco
CollaboratorOTHER
Big Health Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥22 years old * Insomnia Disorder diagnosis * Score ≤16 on the 8-item Sleep Condition Indicator * \> 30 minutes sleep onset latency (SOL); and/or \> 30 minutes wake after sleep onset (WASO) * Current resident of the USA * Oral and written fluency in English * Participant is able and willing to comply with protocol requirements, has been informed of the nature of the study, and has signed the IRB-approved informed consent form

Exclusion criteria

* Must not be currently receiving or be expecting to start CBT for insomnia during study participation, or have previously received CBT for insomnia in the past 12-months (self-report) * If on psychoactive medication, including sleep medication, this must be stable for at least 5 half lives * Past or present psychosis, schizophrenia, bipolar disorder, assessed by self-report and/or seizure disorder * Occupation that requires alertness / caution to avoid accidents, for example long-haul driving, long distance bus driver, heavy machinery operator, air traffic controller * Hearing or vision impairment that prevents effective use of the audio-visual content of digital CBT-I or SHE in the opinion of the investigator * Intellectual disability or any Neurocognitive or Neurodevelopmental disorder that would prevent participants from following study procedures * Any condition that the investigator believes would make participation in the study not in the best interest of the participant or would preclude successful completion of study activities

Design outcomes

Primary

MeasureTime frameDescription
Change in the Insomnia Severity Index (ISI)From baseline to 10 weeks post-randomizationValidated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity
Change in sleep onset latency (SOL)From baseline to 10 weeks post-randomizationMeasured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days
Change in wake after sleep onset (WASO)From baseline to 10 weeks post-randomizationMeasured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days

Secondary

MeasureTime frameDescription
Change in the Sleep Condition Indicator (SCI-8)From baseline to weeks 10, 16, and 24 post-randomizationValidated questionnaire; an 8-item scale with total scores between 0 and 32 where higher scores indicate better sleep
Change in the Generalized Anxiety Disorder Questionnaire (GAD-7)From baseline to weeks 10, 16, and 24 post-randomizationValidated questionnaire; a 7-item scale with total scores between 0 and 21 where higher scores indicate greater severity
Change in the Patient Health Questionnaire (PHQ-8)From baseline to weeks 10, 16 and 24 post-randomizationValidated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity
Insomnia Disorder remission (score <8) and response (change ≥6) on the ISI10, 16, and 24 weeks post-randomizationValidated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity
Change in sleep onset latency (SOL)From baseline to weeks 16 and 24 post-randomizationMeasured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days
Change in wake after sleep onset (WASO)From baseline to weeks 16 and 24 post-randomizationMeasured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days
Change in the Insomnia Severity Index (ISI)From baseline to weeks 16 and 24 post-randomizationValidated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity
Insomnia disorder remission based on the SCID Insomnia ModuleWeek -1 compared to weeks 10, 16, and 24 post-randomizationstructured interview to assess for Insomnia Disorder
Change in sleep diary parameters: percent sleep efficiency (SE), total sleep time (TST), total time in bed (TTIB), and total wake time (TWT)From lead-in period to 10, 16, and 24 weeks post-randomizationEach measured in minutes by daily sleep diaries (based on the Consensus Sleep Diary)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026